Identification of a novel infection-enhancing epitope on dengue prM using a dengue cross-reacting monoclonal antibody

BMC Microbiology

Volumn 13, Issue 1, 2013, Pages

  Luo, Ya Yan ^a   Feng, Jun Jie ^a   Zhou, Jun Mei ^a   Yu, Zhi Zhun ^a   Fang, Dan Yun ^a   Yan, Hui Jun ^a   Zeng, Gu Cheng ^a   Jiang, Li Fang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Antibody dependent enhancement; Dengue virus; Epitope; Phage display peptide library; prM protein

Indexed keywords

EPITOPE; GLYCYLGLUTAMYLPROLYLPROLYLPROLYLGLYCYLLYSYLPROLYLALANYLASPARTYLASPARTYLALANYLGLYCYLLEUCYLVALINE; MONOCLONAL ANTIBODY; PRM PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; BLOCKING ANTIBODY; PEPTIDE LIBRARY; PRM PROTEIN, FLAVIVIRUS; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

AEDES ALBOPICTUS; AMINO ACID ANALYSIS; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT ENHANCEMENT; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CELL STRAIN BHK; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS REACTION; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PEPTIDE LIBRARY; PHAGE DISPLAY; PROTEIN MOTIF; SEROTYPE; SPLEEN CELL; SYRIAN HAMSTER; ADULT; ANIMAL; BAGG ALBINO MOUSE; BIOLOGY; DENGUE VIRUS; EPITOPE MAPPING; FEMALE; IMMUNOLOGY; SERODIAGNOSIS;

ARTHROPODA; DENGUE VIRUS; MUS;

ADULT; ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; COMPUTATIONAL BIOLOGY; CROSS REACTIONS; DENGUE; DENGUE VIRUS; EPITOPE MAPPING; EPITOPES; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PEPTIDE LIBRARY; VIRAL ENVELOPE PROTEINS;

EID: 84883131239     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-13-194     Document Type: Article

References (66)

1. The global distribution and burden of dengue. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI, Nature 2013 496 504 507 10.1038/nature12060 23563266
2. Severe Dengue Virus Infection in Pediatric Travelers Visiting Friends and Relatives after Travel to the Caribbean. Krishnan N, Purswani M, Hagmann S, Am J Trop Med Hyg 2012 86 474 476 10.4269/ajtmh.2012.11-0411 22403320
3. Dengue vaccines: progress and challenges. Coller BG, Clements DE, Curr Opin Immunol 2011 23 1 8 10.1016/j.coi.2010.12.001 21185707
4. Recent progress in dengue vaccine research and development. Miller N, Curr Opin Mol Ther 2010 12 31 38 20140814
5. Dengue hemorrhagic fever in infants: research opportunities ignored. Halstead SB, Lan NT, Myint TT, Shwe TN, Nisalak A, Kalyanarooj S, Nimmannitya S, Soegijanto S, Vaughn DW, Endy TP, Emerg Infect Dis 2002 8 1474 1479 10.3201/eid0812.020170 12498666 (Pubitemid 36008787)
6. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS, Am J Trop Med Hyg 1989 40 444 451 2712199 (Pubitemid 19117544)
7. Antibody-enhanced dengue virus infection in primate leukocytes. Halstead SB, O'Rourke EJ, Nature 1977 265 739 741 10.1038/265739a0 404559 (Pubitemid 8039460)
8. Neutralization and antibody-dependent enhancement of dengue viruses. Halstead SB, Adv Virus Res 1977 60 421 467
9. Dengue vaccine prospects: a step forward. Guy B, Almond J, Lang J, Lancet 2011 377 381 382 21277440
10. Both Viremia and Cytokine Levels Associate with the Lack of Severe Disease in Secondary Dengue 1 Infection among Adult Chinese Patients. Tang Y, Kou Z, Zhang F, Yao X, Liu S, Ma J, Zhou Y, Zhao W, Tang X, Jin X, PLoS One 2010 5 15631 10.1371/journal.pone.0015631 21206915
11. A prospective nested case-control study of dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, Potts JA, Jarman RG, Yoon IK, Gibbons RV, Brion JD, Capeding RZ, PLoS Med 2009 6 1000171 10.1371/journal.pmed.1000171 19859541
12. Dengue virus in blood donations, Puerto Rico, 2005. Mohammed H, Linnen JM, Muñoz-Jordán JL, Tomashek K, Foster G, Broulik AS, Petersen L, Stramer SL, Transfusion 2008 48 1348 1354 10.1111/j.1537-2995.2008.01771.x 18503611
13. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. Halstead SB, J Infect Dis 1979 140 527 533 10.1093/infdis/140.4.527 117061 (Pubitemid 10172725)
14. Monoclonal antibody- mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ, Proc Natl Acad Sci USA 2007 104 9422 9427 10.1073/pnas.0703498104 17517625 (Pubitemid 47185795)
15. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, Johnson S, Diamond MS, Beatty PR, Harris E, PLoS Pathog 2010 6 1000790 10.1371/journal.ppat.1000790 20168989
16. The identification of immunodominant linear epitopes of dengue type 2 virus capsid and NS4a proteins using pin-bound peptides. Anandarao R, Swaminathan S, Khanna N, Virus Res 2005 112 60 68 10.1016/j.virusres.2005.03.022 16022901 (Pubitemid 40966776)
17. A structural perspective of the flavivirus life cycle. Mukhopadhyay S, Kuhn RJ, Rossmann MG, Nat Rev Microbiol 2005 3 13 22 10.1038/nrmicro1067 15608696 (Pubitemid 40028466)
18. Folding and dimerization of tick-borne encephalitis virus envelope proteins prM and E in the endoplasmic reticulum. Lorenz IC, Allison SL, Heinz FX, Helenius A, J Virol 2002 76 5480 5491 10.1128/JVI.76.11.5480-5491.2002 11991976 (Pubitemid 34517898)
19. Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively. Mackenzie JM, Westaway EG, J Virol 2001 75 10787 10799 10.1128/JVI.75.22.10787- 10799.2001 11602720 (Pubitemid 33031548)
20. Structure of the immature dengue virus at low pH primes proteolytic maturation. Yu IM, Zhang W, Holdaway HA, Li L, Kostyuchenko VA, Chipman PR, Kuhn RJ, Rossmann MG, Chen J, Science 2008 319 1834 1837 10.1126/science.1153264 18369148 (Pubitemid 351451592)
21. Dengue virus premembrane and membrane proteins elicit a protective immune response. Bray M, Lai CJ, Virology 1991 185 505 508 10.1016/0042-6822(91)90809- P 1926792
22. Antibodies against prM protein distinguish between previous infection with dengue and Japanese encephalitis viruses. Cardosa MJ, Wang SM, Sum MS, Tio PH, BMC Microbiol 2002 2 9 10.1186/1471-2180-2-9 12019028
23. Retrospective study of Western blot profiles in immune sera of natural dengue virus infections. Se-Thoe SY, Ng MM, Ling AE, J Med Virol 1999 57 322 330 10.1002/(SICI)1096-9071(199903)57:3<322::AID-JMV17>3.0.CO;2-5 10022806 (Pubitemid 29069742)
24. Cross-reacting antibodies enhance dengue virus infection in humans. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, Chawansuntati K, Malasit P, Mongkolsapaya J, Screaton G, Science 2010 328 745 748 10.1126/science.1185181 20448183
25. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. Lai CY, Tsai WY, Lin SR, Kao CL, Hu HP, King CC, Wu HC, Chang GJ, Wang WK, J Virol 2008 82 6631 6643 10.1128/JVI.00316-08 18448542 (Pubitemid 351875140)
26. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F, Cell Host Microbe 2010 8 271 283 10.1016/j.chom.2010.08.007 20833378
27. Immature dengue virus: a veiled pathogen? Rodenhuis-Zybert IA, van der Schaar HM, da Silva Voorham JM, van der Ende-Metselaar H, Lei HY, Wilschut J, Smit JM, PLoS Pathog 2010 6 1000718 10.1371/journal.ppat.1000718 20062797
28. A human PrM antibody that recognizes a novel cryptic epitope on dengue E glycoprotein. Chan AH, Tan HC, Chow AY, Lim AP, Lok SM, Moreland NJ, Vasudevan SG, MacAry PA, Ooi EE, Hanson BJ, PLoS One 2012 7 33451 10.1371/journal.pone. 0033451 22509258
29. Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants. Chau TN, Hieu NT, Anders KL, Wolbers M, Lien LB, Hieu LT, Hien TT, Hung NT, Farrar J, Whitehead S, Simmons CP, J Infect Dis 2009 200 1893 1900 10.1086/648407 19911991
30. Flow Cytometric Determination for Dengue Virus-Infected cells: Its application for Antibody-Dependent Enhancement study. Huang KJ, Yang YC, Lin YS, Liu HS, Yeh TM, Chen SH, Liu CC, Lei HY, Dengue Bulletin 2005 29 142 150
31. The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. Huang KJ, Yang YC, Lin YS, Huang JH, Liu HS, Yeh TM, Chen SH, Liu CC, Lei HY, J Immunol 2006 176 2825 2832 16493039
32. Identification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of dengue type 4 virus. Men R, Yamashiro T, Goncalvez AP, Wernly C, Schofield DJ, Emerson SU, Purcell RH, Lai CJ, J Virol 2004 78 4665 4674 10.1128/JVI.78.9.4665-4674.2004 15078949 (Pubitemid 38501088)
33. B-Cell epitope mapping of the VapA protein of Rhodococcus equi: implications for early detection of R. equi disease in foals. Vanniasinkam T, Barton MD, Heuzenroeder MW, J Clin Microbiol 2001 39 1633 1637 10.1128/JCM.39.4.1633-1637.2001 11283104 (Pubitemid 32275482)
34. Identification of continuous B cell epitopes on the protein moiety of the 58-kiloDalton cell wall mannoprotein of Candida albicans belonging to a family of immunodominant fungal antigens. Viudes A, Perea S, Lopez-Ribot JL, Infect Immun 2001 69 2909 2919 10.1128/IAI.69.5.2909-2919.2001 11292706 (Pubitemid 32332182)
35. Development of a humanized antibody with high therapeutic potential against dengue virus type 2. Li PC, Liao MY, Cheng PC, Liang JJ, Liu IJ, Chiu CY, Lin YL, Chang GJ, Wu HC, PLoS Negl Trop Dis 2012 6 1636 10.1371/journal. pntd.0001636 22563515
36. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE Jr, de Silva AM, Proc Natl Acad Sci USA 2012 109 7439 7444 10.1073/pnas.1200566109 22499787
37. Analysis of Epitopes on Dengue Virus Envelope Protein Recognized by Monoclonal Antibodies and Polyclonal Human Sera by a High Throughput Assay. Lin HE, Tsai WY, Liu IJ, Li PC, Liao MY, Tsai JJ, Wu YC, Lai CY, Lu CH, Huang JH, Chang GJ, Wu HC, Wang WK, PLoS Negl Trop Dis 2012 6 1447 10.1371/journal.pntd. 0001447 22235356
38. Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement. Hughes HR, Crill WD, Chang GJ, Virol J 2012 9 115 10.1186/1743-422X-9-115 22709350
39. Recombinant dengue type 2 viruses with altered E protein domain III epitopes are efficiently neutralized by human immune sera. Wahala WM, Huang C, Butrapet S, White LJ, de Silva AM, J Virol 2012 86 4019 4023 10.1128/JVI.06871-11 22278250
40. Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins. Falconar AK, Arch Virol 1999 144 2313 2330 10.1007/s007050050646 10664386 (Pubitemid 30057171)
41. Anti-prM Antibody as an Autoantibody in Dengue Virus Infection. Huang KJ, Lin YS, Cheng YT, Huang JH, Liu HS, Yeh TM, Liu CC, Lei HY, Am J Infect Dis 2008 4 59 67
42. Functional importance of dengue virus maturation: infectious properties of immature virions. Rodenhuis-Zybert IA, van der Ende-Metselaar H, Wilschut J, Smit JM, J Gen Virol 2008 89 3047 3051 10.1099/vir.0.2008/002535-0 19008392
43. Continuous cultures of fused cells secreting antibody of predefined specificity. Kohler G, Milstein C, Nature 1975 256 495 497 10.1038/256495a0 1172191
44. Rapid detection and identification of dengue viruses by polymerase chain reaction (PCR). Yenchitsomanus PT, Sricharoen P, Jaruthasana I, Pattanakitsakul SN, Nitayaphan S, Mongkolsapaya J, Malasit P, Southeast Asian J Trop Med Public Health 1996 27 228 236 9279982 (Pubitemid 126470742)
45. An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate. Innis BL, Nisalak A, Nimmannitya S, Kusalerdchariya S, Chongswasdi V, Suntayakorn S, Puttisri P, Hoke CH, Am J Trop Med Hyg 1989 40 418 427 2540664 (Pubitemid 19117542)
46. Prediction of protein antigenic determinants from amino acid sequences. Hoop TP, Woods KR, Proc Natl Acad Sci USA 1981 78 3824 3828 10.1073/pnas.78.6. 3824 6167991 (Pubitemid 11060471)
47. Amino acid difference formula to help explain protein evolution. Grantham R, Science 1974 185 862 864 10.1126/science.185.4154.862 4843792
48. The anigenic index: a novel algorithm for predicting antigenic determinants. Jameson BA, Wolf H, Comput Appl Biosci 1988 4 181 186 2454713 (Pubitemid 18072035)
49. Positional flexibilities of amino acid residues in globular proteins. Bhaskaran R, Ponnuswamy PK, Int J Peptide Protein Res 1988 32 241 255
50. Induction of hepatitis A virus- neutralizing antibody by a virus specific synthetic peptide. Emini EA, Hughes JV, Perlow DS, Boger J, J Virol 1985 55 836 839 2991600 (Pubitemid 16254565)
51. An algorithm for protein secondary structure prediction based on class prediction. Deleage G, Roux B, Protein Eng 1987 1 289 294 10.1093/protein/1.4. 289 3508279 (Pubitemid 18024006)
52. Development of TaqMan MGB probe-based real-time fluorescence quantitative reverse transcription PCR for dengue virus and its application. Luo YY, Feng JJ, Fang DY, Jiang LF, J Mol Diagn Ther 2012 4 158 162
53. Binding of a neutralizing antibody to dengue virus alters the arrangementof surface glycoproteins. Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, Sukupolvi-Petty S, Sedlak D, Fremont DH, Chipman PR, Roehrig JT, Diamond MS, Kuhn RJ, Rossmann MG, Nat Struct Mol Biol 2008 15 312 317 10.1038/nsmb.1382 18264114 (Pubitemid 351654038)
54. Antibodies against the Envelope Glycoprotein Promote Infectivity of Immature Dengue Virus Serotype 2. da Silva Voorham JM, Rodenhuis-Zybert IA, Ayala Nuñez NV, Colpitts TM, van der Ende-Metselaar H, Fikrig E, Diamond MS, Wilschut J, Smit JM, PLoS One 2012 7 29957 10.1371/journal.pone.0029957 22431958
55. Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal DENV infection. Kaufman BM, Summers PL, Dubois DR, Cohen WH, Gentry MK, Am J Trop Med Hyg 1989 41 576 580 2817214 (Pubitemid 20000630)
56. Partial maturation: an immune-evasion strategy of dengue virus? Rodenhuis-Zybert IA, Wilschut J, Smit JM, Trends Microbiol 2011 19 248 254 10.1016/j.tim.2011.02.002 21388812
57. Flaviviridae: the viruses and their replication. Lindenbach BD, Thiel HJ, Rice CM, In Fields virology, Volume Philadelphia: Lippincott William and Wilkins, Knipe DM, Howley PM, 5 2001 1101 1152
58. Enzyme-linked immunosorbent assays using novel Japanese encephalitis virus antigen improve the accuracy of clinical diagnosis of flavivirus infections. Chiou SS, Crill WD, Chen LK, Chang GJ, Clin Vaccine Immunol 2008 15 825 835 10.1128/CVI.00004-08 18337381 (Pubitemid 351967016)
59. Immune response to synthetic peptides of dengue prM protein. Vázquez S, Guzmán MG, Guillen G, Chinea G, Pérez AB, Pupo M, Rodriguez R, Reyes O, Garay HE, Delgado I, García G, Alvarez M, Vaccine 2002 20 1823 1830 10.1016/S0264-410X(01)00515-1 11906771 (Pubitemid 34242839)
60. Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking. van der Schaar HM, Rust MJ, Waarts BL, van der Ende-Metselaar H, Kuhn RJ, Wilschut J, Zhuang X, Smit JM, J Virol 2007 81 12019 12028 10.1128/JVI.00300-07 17728239 (Pubitemid 47623832)
61. Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. Cherrier MV, Kaufmann B, Nybakken GE, Lok SM, Warren JT, Chen BR, Nelson CA, Kostyuchenko VA, Holdaway HA, Chipman PR, Kuhn RJ, Diamond MS, Rossmann MG, Fremont DH, EMBO J 2009 28 3269 3276 10.1038/emboj.2009.245 19713934
62. Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles. Junjhon J, Edwards TJ, Utaipat U, Bowman VD, Holdaway HA, Zhang W, Keelapang P, Puttikhunt C, Perera R, Chipman PR, Kasinrerk W, Malasit P, Kuhn RJ, Sittisombut N, J Virol 2010 84 8353 8358 10.1128/JVI.00696-10 20519400
63. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. Nelson S, Jost CA, Xu Q, Ess J, Martin JE, Oliphant T, Whitehead SS, Durbin AP, Graham BS, Diamond MS, Pierson TC, PLoS Pathog 2008 4 1000060 10.1371/journal.ppat.1000060 18464894 (Pubitemid 351811531)
64. Neutralization and antibody-dependent enhancement of dengue viruses. Halstead SB, Adv Virus Res 2003 60 421 467 14689700 (Pubitemid 137639381)
65. Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies. Henchal EA, McCown JM, Burke DS, Seguin MC, Brandt WE, Am J Trop Med Hyg 1985 34 162 169 2578750 (Pubitemid 15174332)
66. Acidotropic amines inhibit proteolytic processing of flavivirus prM protein. Randolph VB, Winkler G, Stollar V, Virology 1990 174 450 458 10.1016/0042-6822(90)90099-D 2154882 (Pubitemid 20060149)